Charles Schwab Investment Management Inc. Boosts Stock Position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX)

Charles Schwab Investment Management Inc. boosted its position in Black Diamond Therapeutics, Inc. (NASDAQ:BDTX) by 6.9% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 109,224 shares of the company’s stock after purchasing an additional 7,021 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.19% of Black Diamond Therapeutics worth $475,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. Ally Bridge Group NY LLC acquired a new stake in shares of Black Diamond Therapeutics in the 2nd quarter worth $3,891,000. Affinity Asset Advisors LLC purchased a new stake in Black Diamond Therapeutics in the second quarter valued at about $3,029,000. TD Asset Management Inc boosted its holdings in Black Diamond Therapeutics by 275.9% in the second quarter. TD Asset Management Inc now owns 266,312 shares of the company’s stock worth $1,241,000 after acquiring an additional 195,464 shares in the last quarter. Renaissance Technologies LLC grew its stake in shares of Black Diamond Therapeutics by 24.1% during the second quarter. Renaissance Technologies LLC now owns 263,900 shares of the company’s stock worth $1,230,000 after acquiring an additional 51,300 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Black Diamond Therapeutics by 79.1% during the second quarter. Dimensional Fund Advisors LP now owns 200,044 shares of the company’s stock valued at $932,000 after acquiring an additional 88,378 shares in the last quarter. 95.47% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on BDTX. Wedbush reiterated an “outperform” rating and issued a $16.00 target price on shares of Black Diamond Therapeutics in a research note on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Black Diamond Therapeutics in a report on Wednesday, November 6th. Finally, Piper Sandler boosted their price objective on shares of Black Diamond Therapeutics from $12.00 to $15.00 and gave the company an “overweight” rating in a report on Monday, September 23rd.

Black Diamond Therapeutics Stock Down 6.4 %

Black Diamond Therapeutics stock opened at $2.19 on Friday. Black Diamond Therapeutics, Inc. has a 52 week low of $2.18 and a 52 week high of $7.66. The stock has a 50-day moving average price of $2.82 and a 200 day moving average price of $4.39. The company has a market capitalization of $123.92 million, a price-to-earnings ratio of -1.65 and a beta of 2.47.

Black Diamond Therapeutics (NASDAQ:BDTX) last announced its quarterly earnings data on Tuesday, November 5th. The company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.09. Research analysts anticipate that Black Diamond Therapeutics, Inc. will post -1.3 EPS for the current fiscal year.

Black Diamond Therapeutics Profile

Black Diamond Therapeutics, Inc, a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma.